comparemela.com

Latest Breaking News On - Uk azn - Page 5 : comparemela.com

AbbVie Buys Cerevel for $9 Billion in All-Cash Deal

AbbVie said late Wednesday it will buy Cerevel Therapeutics for $45 a share, or about $8.7 billion, in an all-cash deal.

Brian swintCerevel therapeuticsAbbot laboratoriesArticle normalBiotechnology servicesRetail wholesaleHealthcare life sciencesOwnership changesAcquisitions mergers shareholdingsAcquisitions mergersCorporate actionsCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filterBiotech and pharma

Pharma Stocks With Nice Dividends: the RX Investors Need

Healthcare stocks like AbbVie and Johnson & Johnson are cash rich and offer solid dividend growth.

Daniel lyonsChris senyekRandy ackerChris dagnesWolfe researchHealth care select sectorJanus henderson global life sciencesStephanie linkHamlin capital managementAbbot laboratoriesArticle normalHealthcare life sciencesFinancial performanceSales figuresCorporate actionsCorporate industrial news

Johnson & Johnson and Other Pharma Stocks With Nice Dividends

Healthcare stocks like AbbVie and Johnson & Johnson are cash rich and offer solid dividend growth.

Chris dagnesChris senyekDaniel lyonsRandy ackerWolfe researchHealth care select sectorJanus henderson global life sciencesStephanie linkHamlin capital managementAbbot laboratoriesArticle normalHealthcare life sciencesFinancial performanceSales figuresCorporate actionsCorporate industrial news

AstraZeneca Launches Health-Tech Business Evinova -- Update

By Michael Susin AstraZeneca said it has launched Evinova, a separate health-tech business to offer its knowledge of clinical-trial design and study.

Michael susinArticle normalBiotechnology servicesHealthcare life sciencesNew products servicesCorporate industrial newsProducts servicesContent typesFactiva filtersC amp ampe industry news filterAzn lnUk aznNew productsIndustrial newsLife sciences

AstraZeneca Agrees on Licensing Deal for Obesity Treatment

By Joe Hoppe AstraZeneca said it has entered an exclusive agreement with Eccogene, licensing the latter's ECC5004 product for treating conditions such as.

Joe hoppeArticle normalBiotechnology servicesHealthcare life sciencesPolitical general newsSociety communityMedical conditionsSocial issuesAzn lnUk aznGeneral newsLife sciences

vimarsana © 2020. All Rights Reserved.